Table 1.

Entrya	Anti-proliferationb		Her2 ELISAc	Luc. Refoldingd
	MCF-7	SkBr3	SkBr3
1	>100e	42 ± 4	67 ± 8	13 ± 4
2	41 ± 12	55 ± 8	64 ± 15	NI
3	>100	>100	>100	NI
4	>100	>100	>100	15 ± 0.6
5	>100	>100	>100	4.4 ± 1.5
6	4 ± 1	23 ± 0.5	33 ± 6	36 ± 2
7	44 ± 8	55 ± 1	61 ± 1	15 ± 0.6
8	>100	>100	>100	55 ± 9
9	3.0 ± 0.8	2.4 ± 1.1	4.4 ± 2.1	16 ± 1
10	>100	>100	>100	2.1 ± 0.2
11	25 ± 11	9.0 ± 0.3	8.9 ± 3.4	7.0 ± 0.4
12	19 ± 4	7.8 ± 0.3	4.7 ± 1.7	120 ± 8
13	>100	>100	>100	22 ± 0.5
14	93 ± 7	76 ± 12	44 ± 4.5	23 ± 8
15	2.1 ± 0.8	15 ± 1	12.5 ± 3.6	1.9 ± 0.3
16	9.1 ± 4	15 ± 6.2	10.9 ± 0.4	6.7 ± 2
17	>100	25 ± 3.6	21.3 ± 14	15 ± 12
18	>100	>100	>100	190 ± 4
19	34 ± 13	39 ± 2.1	51.6 ± 7	4.5 ± 0.3
20	>100	>100	>100	0.12 ± 0.6

^aCompounds correspond to scaffolds shown in Figure 5.

^bAnti-proliferation assays were performed as described in Section 5.8.

^cHer2 ELISA assays were performed as described in Section 5.9.

^dLuciferase refolding assays were performed as described in Section 5.7.

^eValues represent Mean IC₅₀ ± SE of at least two separate experiments performed in triplicate (μM).